HypokalemiaMANAGEMENT

ENDOCRINE AND METABOLIC PRESENTATIONS · 12 SECTIONS

⚲

549 items

☷ Legend

⚲

Cardiovascular Presentations71▾

Respiratory Presentations52▾

Neurological Presentations83▾

Gastrointestinal Presentations74▾

Genitourinary and Reproductive Presentations48▾

Infectious Disease Presentations148▾

Trauma Presentations89▾

Toxicologic Presentations80▾

Psychiatric Presentations26▾

Musculoskeletal and Rheumatologic Presentations96▾

Dermatology Presentations23▾

Environmental and Exposure Presentations27▾

Hematologic and Oncologic Presentations36▾

Pediatric-Specific Presentations19▾

Endocrine and Metabolic Presentations45▾

Acute Porphyria Adrenal crisis Adrenal Insufficiency (Addisonian Crisis)Dehydration Diabetes Insipidus Diabetic Ketoacidosis (DKA)Euglycemic DKA (SGLT2 inhibitor)Galactosemia GLP-1 receptor agonist complications (retained gastric contents, aspiration risk)Homocystinuria Hypercalcemia Hyperkalemia Hypermagnesemia Hypernatremia Hyperosmolar Hyperglycemic State (HHS)Hypertensive emergency Hypertensive urgency Hypocalcemia Hypoglycemia Hypogonadism (Acute Presentation)Hypokalemia Hypomagnesemia Hyponatremia Hypoparathyroidism (Tetany)Insulin pump failure Maple Syrup Urine Disease (Crisis)Medium-Chain Acyl-CoA Dehydrogenase Deficiency (MCAD)Metabolic Acidosis Metabolic Alkalosis Myasthenia gravis crisis Myxedema coma Pellagra Pheochromocytoma (Crisis)Pituitary Apoplexy Pompe Disease (GSD II)Respiratory Acidosis Respiratory Alkalosis Scurvy SIADH Starvation Ketosis Tarui Disease (GSD VII)Thyroid storm Tyrosinemia Vitamin D Deficiency (Severe-Rickets)Von Gierke Disease (GSD I)

ENT and Maxillofacial Presentations27▾

Ophthalmologic Presentations19▾

Obstetric Presentations23▾

Systemic and Miscellaneous Presentations17▾

01Approach to the Critical Patient/attcp41

Immediate priorities

›Life-threatening presentations requiring immediate action

›Cardiac arrest or malignant arrhythmia

›Ventricular tachycardia or ventricular fibrillation

›Torsades de pointes from QTc prolongation

›Defibrillation plus IV KCl and magnesium simultaneously

›Respiratory failure from diaphragmatic weakness

›SpO2 < 90% with shallow respirations

›Rising PaCO2 indicating impending failure

›Early intubation planning when K+ < 2.0 mmol/L with respiratory symptoms

›Ascending paralysis

›Proximal limb weakness progressing to trunk and respiratory muscles

›Immediate IV replacement regardless of GI tolerance

›ICU-level monitoring required

Hemodynamic goals and monitoring

›Cardiac monitoring targets

›Continuous cardiac telemetry for K+ < 3.0 mmol/L

›12-lead ECG on all confirmed hypokalemia patients

›QTc threshold for urgent treatment: QTc > 500 ms

›Repeat ECG after every 20 mEq IV KCl in symptomatic patients

›IV access and fluid strategy

›Peripheral IV adequate for rates up to 10 mEq/hour

›Central venous access required for rates > 20 mEq/hour

›Glucose-free IV fluids only — dextrose drives K+ intracellularly

›Normal saline preferred carrier for IV KCl

Escalation triggers

›Escalate to resuscitation bay or ICU for

›K+ < 2.0 mmol/L with any symptom

02History/hx51

Presenting symptoms

›Classic symptom complex

›Muscle weakness (proximal > distal)

›Muscle cramps and myalgias

›Palpitations or irregular heartbeat

›Fatigue and malaise

›Constipation or abdominal distension

›Paresthesias (perioral or extremity tingling)

›Severe or alarming symptoms

›Ascending limb weakness or inability to walk

›Dyspnea or shallow breathing

›Syncope or presyncope

›Chest pain with palpitations

Medication review

›Causative medications

›Thiazide diuretics: 11-fold increased risk; average K+ decrease ~0.6 mmol/L

›Loop diuretics: average K+ decrease ~0.3 mmol/L; dose-dependent

›Laxatives (chronic use)

›Corticosteroids (systemic)

›Beta-agonists (albuterol, salmeterol)

›Insulin (acute transcellular shift)

›Amphotericin B (renal tubular toxicity)

›Aminoglycosides (renal wasting)

›Cisplatin (renal wasting)

›Potentiating medications

›Digoxin: does not cause hypokalemia but greatly increases toxicity

›QT-prolonging medications: risk of torsades de pointes when combined with hypokalemia

03Physical Exam/exam33

Vital signs and general

›Hemodynamic assessment

›Heart rate: tachycardia from arrhythmia or volume depletion

›Blood pressure: hypotension if volume depleted; hypertension if hyperaldosteronism

›Respiratory rate: shallow or labored breathing indicates muscle weakness

›Oxygen saturation on room air

›General appearance

›Cushingoid features (moon facies, central obesity, striae) suggesting cortisol excess

›Signs of dehydration (dry mucosa, poor skin turgor)

Neurologic and musculoskeletal exam

›Muscle strength assessment

›Proximal muscle groups: hip flexors (cannot rise from chair), deltoids

›Distal muscle groups: hand grip, dorsiflexion

›Ascending pattern: lower limbs before upper limbs in severe cases

›Deep tendon reflexes

›Hyporeflexia or areflexia in moderate to severe hypokalemia

›Decreased muscle tone

›Respiratory muscle function

›Accessory muscle use

›Paradoxical abdominal movement (diaphragmatic weakness)

Cardiac exam

›Rhythm assessment

›Irregular pulse suggesting arrhythmia

›New murmur evaluation

›ECG-correlated findings

›Bradycardia from AV block in severe cases

›Palpable irregular pulse from PVCs

04Differential Diagnosis/ddx39

Transcellular redistribution (not true depletion)

›Alkalosis-driven shift

›Metabolic alkalosis (every 0.1 unit pH rise lowers K+ ~0.5 mmol/L)

›Respiratory alkalosis

›ICD-10 E87.3 (alkalosis)

›Hormone and drug-mediated shift

›Insulin administration

›Beta-2 agonist excess (albuterol nebulization)

›Thyrotoxic periodic paralysis: episodic weakness + low K+ + hyperthyroidism

›Refeeding syndrome (phosphate, K+, Mg shift intracellularly)

›Pseudohypokalemia

›Delayed sample processing with WBC > 100,000/mm3

›Repeat with prompt processing on ice

Renal potassium losses

›Mineralocorticoid excess

›Primary hyperaldosteronism (Conn syndrome): hypertension + hypokalemia; ICD-10 E26.0

›Cushing syndrome: elevated cortisol with mineralocorticoid activity; ICD-10 E24

›Licorice or fludrocortisone use (apparent mineralocorticoid excess)

›Tubular disorders

›Renal tubular acidosis type 1 (distal): hypokalemia + non-anion gap acidosis; ICD-10 N25.89

›Bartter syndrome: salt wasting, hypokalemia, alkalosis, normal blood pressure; ICD-10 Q87.89

›Gitelman syndrome: like Bartter but milder, hypomagnesemia, hypocalciuria; ICD-10 Q87.89

›Diuretic effect

›Thiazides and loops: most common etiology in ED

›Osmotic diuresis from DKA or hyperglycemia

Gastrointestinal losses

›Upper GI losses

›Vomiting: metabolic alkalosis drives renal K+ wasting (urine Cl < 10 mEq/L)

05Laboratory Tests/lt44

Serum electrolytes

›Potassium confirmation

›Serum K+ < 3.5 mmol/L confirms diagnosis (ICD-10 E87.6)

›Severity: mild 3.0-3.5, moderate 2.5-2.9, severe < 2.5 mmol/L

›Repeat sample if unexpected result (pseudohypokalemia consideration)

›1 mmol/L drop in serum K+ represents 200-400 mEq total body deficit

›Basic metabolic panel

›Sodium, chloride, bicarbonate for acid-base classification

›Metabolic alkalosis common with vomiting or diuretics

›BUN and creatinine for renal function assessment

›Glucose for DKA screening

›Magnesium

›Hypomagnesemia present in 40-60% of hypokalemic patients

›Concurrent Mg < 0.7 mmol/L makes hypokalemia refractory to replacement

›Correct magnesium before or simultaneously with potassium

›Phosphate and calcium

›Phosphate: low in refeeding syndrome

›Calcium: hypercalcemia can accompany hyperaldosteronism

Urine electrolytes

›Spot urine potassium

›Urine K+ > 15-30 mEq/day indicates renal wasting

›Urine K+-to-creatinine ratio > 13 mEq/g suggests renal losses

›Urine chloride

›Low urine Cl < 10 mEq/L indicates GI or prior diuretic use (vomiting)

›High urine Cl > 20 mEq/L suggests active diuretic effect or mineralocorticoid excess

›24-hour urine potassium

›> 15-30 mEq/day: renal losses

›< 15 mEq/day: extrarenal losses (GI, inadequate intake)

06Diagnostic Tests/dt52

Scoring Systems

›Severity classification system

›Mild hypokalemia: K+ 3.0-3.5 mmol/L

›Usually asymptomatic

›Outpatient oral replacement appropriate in most cases

›Moderate hypokalemia: K+ 2.5-2.9 mmol/L

›May have fatigue, cramps, mild weakness

›Oral replacement if no severe features; IV if symptomatic

›Severe hypokalemia: K+ < 2.5 mmol/L

›Approximately 50% symptomatic

›High risk for arrhythmia, paralysis, respiratory failure

›IV replacement and cardiac monitoring required

›ECG risk stratification

›No ECG changes: lower urgency but still monitor

›U waves or T flattening: moderate urgency, oral or slow IV

›ST depression or QTc prolongation: high urgency, IV replacement

›QTc > 500 ms or arrhythmia: emergent IV replacement with telemetry

Scoring Systems — Transtubular Potassium Gradient

›TTKG (transtubular potassium gradient) — historical tool

›TTKG = (urine K+ / serum K+) divided by (urine osmolality / serum osmolality)

›TTKG > 4 suggests renal potassium wasting

›TTKG < 2 suggests extrarenal cause

›Now considered less reliable; urine K/creatinine ratio preferred

MRI

›MRI in hypokalemia workup

›Not routinely indicated for hypokalemia diagnosis or management

›MRI adrenals for suspected adrenal adenoma (Conn syndrome) if CT adrenals inconclusive

›Characterization of adrenal lesions > 1 cm

07Disposition/dispo36

ICU admission indications

›ICU or step-down required for

›K+ < 2.0 mmol/L regardless of symptoms

›Ventricular arrhythmia (VT, VF, torsades de pointes)

›Ascending paralysis or respiratory muscle compromise

›Concurrent digoxin toxicity

›Need for IV replacement > 20 mEq/hour (central access required)

›Rhabdomyolysis with renal injury

Telemetry admission indications

›Telemetry ward appropriate for

›K+ 2.0-2.5 mmol/L with ECG changes

›Active cardiac disease (MI, heart failure, LV hypertrophy) with any hypokalemia

›Concurrent QT-prolonging medications

›Ongoing GI losses requiring IV replacement

›Refractory hypokalemia (failure to correct with 60 mEq replacement)

›Cirrhosis with hepatic encephalopathy risk

Observation or ED extended care

›Observation appropriate for

›K+ 2.5-3.0 mmol/L without severe features

›IV or oral replacement in progress with reassessment planned

›Repeat K+ after 2-4 hours to confirm correction

›Discharge if K+ improves, symptoms resolve, cause identified

Discharge criteria

›Safe for discharge when

›K+ 3.0-3.5 mmol/L (mild), asymptomatic, no ECG changes

›Clear etiology identified (e.g., diuretic-related)

›Oral KCl prescription provided

›Reliable follow-up arranged within 1-3 days for recheck

08Treatment/t60

IV potassium replacement — emergency and severe

›Cardiac arrest or malignant arrhythmia from hypokalemia

›IV KCl 5-10 mEq IV push over 15-30 minutes with continuous cardiac monitoring

›Repeat bolus until arrhythmia suppressed and K+ > 3.0 mmol/L

›Followed by maintenance infusion

›Severe hypokalemia (K+ < 2.5 mmol/L) with symptoms

›IV KCl 20-40 mEq in 100 mL normal saline over 2-4 hours

›Maximum safe peripheral rate: 10 mEq/hour

›Rate up to 20 mEq/hour acceptable with continuous telemetry

›Rates > 20 mEq/hour require central venous access

›Glucose-free IV fluids only

›Check serum K+ every 2-4 hours during IV replacement

›Maximum replacement: up to 200-400 mEq/day in severe cases under monitoring

Oral potassium replacement — moderate and mild

›Oral KCl (preferred formulation)

›Dose: 40-100 mEq/day in 2-5 divided doses

›Maximum per dose: 40 mEq

›Maximum per day: 200 mEq

›Take with food to minimize GI irritation

›Rule of thumb: 20 mEq oral KCl raises serum K+ by ~0.2 mmol/L

›KCl superior to other formulations: up to 40% better absorption

›Alternative formulations

›Potassium bicarbonate or citrate: preferred in metabolic acidosis (RTA)

›Potassium phosphate: concurrent hypophosphatemia (refeeding syndrome)

›Contraindications

›Concurrent triamterene or amiloride: contraindicated with KCl

›Caution with ACE inhibitors, ARBs, spironolactone, NSAIDs (rebound hyperkalemia risk)

09Special Populations/sp52

Pregnancy

›Physiologic changes affecting potassium

›Plasma volume expansion dilutes serum K+

›Elevated aldosterone in normal pregnancy promotes renal K+ wasting

›Progesterone partially antagonizes aldosterone, limiting net loss

›Causes specific to pregnancy

›Hyperemesis gravidarum: severe vomiting causing significant GI and renal losses

›K+ can fall below 2.5 mmol/L in severe cases

›IV hydration with KCl required

›Pre-eclampsia treatment: magnesium sulfate may mask neurologic signs of hypokalemia

›Treatment in pregnancy

›Oral KCl preferred for mild-moderate hypokalemia (safe throughout pregnancy)

›IV KCl for severe or symptomatic hypokalemia

›Same dosing as non-pregnant adults

›Fetal cardiac monitoring for K+ < 2.5 mmol/L with IV replacement

›Diuretic use in pregnancy: thiazides generally avoided; loop diuretics restricted

›Potassium-sparing diuretics: limited safety data in pregnancy

Geriatric

›Heightened risk profile

›Polypharmacy: multiple diuretics, laxatives, corticosteroids common

›Decreased renal concentrating ability limits compensation

›Decreased muscle mass reduces total body potassium reserve

›Higher prevalence of underlying cardiac disease (lower arrhythmia threshold)

›Atypical presentations

›Weakness misattributed to deconditioning or sarcopenia

›Falls from proximal muscle weakness

›Confusion or delirium as presenting feature

›Constipation and ileus more pronounced

10Background/b67

Epidemiology

›Prevalence and incidence

›Most common electrolyte abnormality in the emergency department

›ED prevalence approximately 5.5%

›General hospitalized patients: 20% have K+ < 3.5 mmol/L at some point

›Community prevalence: ~2-3% of general population

›Mortality and morbidity

›K+ < 3.0 mmol/L associated with increased all-cause mortality (adjusted HR 1.49)

›Ventricular arrhythmias are the leading cause of hypokalemia-related death

›In heart failure: even K+ 3.5-4.0 mmol/L increases ventricular arrhythmia risk

›ECG abnormalities present in ~40% of hypokalemic ED patients

›T-wave flattening: 27%

›ST depression: 16%

›QTc prolongation: 14%

›High-risk populations

›Heart failure on diuretics

›Cirrhosis with secondary hyperaldosteronism

›Patients on digoxin (narrow therapeutic index)

›Patients receiving chemotherapy (cisplatin, amphotericin)

Pathophysiology

›Normal potassium homeostasis

›98% of total body K+ is intracellular (primarily muscle and liver)

›Normal total body K+: 3,000-4,000 mEq

›Serum K+ reflects extracellular fraction and is tightly regulated 3.5-5.0 mmol/L

›Mechanisms of hypokalemia

›Transcellular shift into cells

›Alkalosis: each 0.1 pH unit rise shifts K+ down ~0.5 mmol/L

›Insulin activation of Na-K-ATPase

›Beta-2 adrenergic stimulation (catecholamine surge, albuterol)

›Thyrotoxic excess: TSH-stimulated Na-K-ATPase activity

›Renal potassium wasting

›Aldosterone activates principal cell ENaC and K+ channels in collecting duct

›Diuretics block upstream Na+ reabsorption, increasing distal delivery and K+ secretion

›High urine flow rate (osmotic diuresis) washes out K+

›RTA type 1: failure of H+ secretion impairs K+ reabsorption

›GI potassium losses

›Vomiting causes metabolic alkalosis, which drives renal K+ wasting (urine Cl < 10 mEq/L is key clue)

›Diarrhea: direct colonic K+ loss (stool K+ 70-90 mEq/L in secretory diarrhea)

›Cardiac electrophysiology effects

›Hyperpolarizes resting membrane potential

›Prolonged phase 3 repolarization increases arrhythmia susceptibility

›U waves represent delayed Purkinje fiber repolarization

›Torsades de pointes: polymorphic VT triggered by prolonged QTc from hypokalemia

›Neuromuscular effects

›Reduced resting membrane potential impairs action potential generation

›Proximal muscle weakness before distal (higher metabolic demand)

›Smooth muscle: ileus from decreased gut peristalsis

Therapeutic Considerations

›Potassium replacement rationale

›Target K+ > 3.5 mmol/L for most patients

›Target K+ > 4.0 mmol/L for heart failure, active ischemia, or digoxin use

›KCl is preferred salt: corrects concurrent hypochloremia and metabolic alkalosis

›Potassium bicarbonate preferred in metabolic acidosis with hypokalemia (RTA)

›Magnesium dependency

›Mg is required cofactor for Na-K-ATPase activity

›Low Mg impairs K+ reabsorption in loop of Henle

›Hypokalemia will not correct without simultaneous Mg repletion

›Class I recommendation: check and correct Mg in all hypokalemic patients

›Diuretic pharmacology

›Thiazide effect: blocks NaCl cotransporter in distal tubule, increasing K+ secretion

›11-fold higher risk of hypokalemia vs non-use

›Average K+ decrease: ~0.6 mmol/L

›Loop diuretic effect: blocks NKCC2 in thick ascending limb

›Average K+ decrease: ~0.3 mmol/L; dose-dependent in heart failure

›Potassium-sparing diuretics: spironolactone blocks aldosterone; amiloride blocks ENaC

›Evidence levels

›Correction of hypomagnesemia before K+ replacement: Class I recommendation

›IV replacement for K+ < 2.5 mmol/L or ECG changes: Class I recommendation

›Avoid glucose-containing IV fluids during K+ replacement: ACEP Level B recommendation

›Target K+ > 4.0 mmol/L in heart failure patients: Class IIa recommendation (JACC)

11Patient Discharge Instructions/pdi32

copy discharge instructions

›What is hypokalemia

›Low potassium level in your blood

›Potassium is essential for your heart, muscles, and nerves to work properly

›Your potassium level today and what it means

›Mild (3.0-3.5 mmol/L): usually manageable with diet and medication changes

›Moderate (2.5-2.9 mmol/L): requires oral potassium supplements

›You were treated in the emergency department and your level improved

›Take your potassium supplement exactly as prescribed

›Take with food or a full glass of water to avoid stomach upset

›Do not crush or chew extended-release tablets

›Do not take more than the prescribed dose

›Eat potassium-rich foods

›Bananas, oranges, avocados, tomatoes, spinach, potatoes

›Beans, dairy products, nuts, and seeds

›Reduce salt intake: high sodium promotes potassium loss from kidneys

›Take all medications as prescribed

›If your doctor changed your diuretic (water pill) dose, follow the new instructions

›Do not stop any heart or blood pressure medications without asking your doctor first

›Avoid these until your potassium is normal

›Excessive laxative use

›Heavy alcohol intake

›Sports drinks or other drinks that are high in sugar (promote potassium shifts)

›Your follow-up appointment

›Blood test to recheck potassium within 1-3 days (moderate) or within 1 week (mild)

›See your family doctor or specialist to determine the cause

›Return to the emergency department immediately if you experience

›Palpitations, rapid heartbeat, or irregular heartbeat

12References/r42

Guidelines and key sources

›Kim MJ, Valerio C, Knobloch GK

›Potassium Disorders: Hypokalemia and Hyperkalemia

›American Family Physician 2023

›PMID 36689973

›Kildegaard H, Brabrand M, Forberg JL, et al

›Prevalence and Prognostic Value of Electrocardiographic Abnormalities in Hypokalemia: A Multicenter Cohort Study

›Journal of Internal Medicine 2024

›PMID 38098171

›Gennari FJ

›Hypokalemia

›New England Journal of Medicine 1998

›NEJM 339:451-458

›Ferreira JP, Butler J, Rossignol P, et al

›Abnormalities of Potassium in Heart Failure: JACC State-of-the-Art Review

›Journal of the American College of Cardiology 2020

›PMID 32498812

›Lin Z, Wong LYF, Cheung BMY

›Diuretic-Induced Hypokalaemia: An Updated Review

›Postgraduate Medical Journal 2022

›PMID 33688065

›Oswald S, Ravioli S, Schwarz C, Lindner G

›Hypokalaemia in the Emergency Department: Aetiology, Diagnosis, and Management

›Swiss Medical Weekly 2026

›PMID 41962024

›Sandau KE, Funk M, Auerbach A, et al

›Update to Practice Standards for Electrocardiographic Monitoring in Hospital Settings

›American Heart Association Scientific Statement, Circulation 2017

Learn More: Hypokalemia→

Comprehensive Clinical Review

Structured, evidence-informed, long-form analysis for deeper understanding.

Evidence & Review

Reviewed by SymptomDx Medical Team · Last reviewed August 18, 2026

SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.